iPierian designates Nancy Stagliano as CEO
Stagliano, recently served as the CEO and co-founder of CytomX Therapeutics, will succeed interim CEO Peter Van Vlasselear. Earlier, she worked as the COO of CytomX, which launched
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.
Afatinib is an experimental orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically epidermal growth factor receptor (EGFR) and HER2. The trials, 1200.89, ‘Afatinib (BIBW